Related Experiment Videos
Two-year survival after myocardial infarction.
C G Ericsson1, L Erhardt, N Rehnqvist
1Department of Medicine, Karolinska Institute, Danderyd Hospital, Sweden.
Journal of Internal Medicine
|March 1, 1990
Summary
This study on myocardial infarction patients found that early intervention and structured follow-up, including exercise ECGs, improved outcomes. Beta-blocker use was common, even in heart failure cases.
Area of Science:
- Cardiology
- Internal Medicine
- Clinical Research
Background:
- Myocardial infarction (MI) poses a significant public health challenge.
- Effective management strategies are crucial for reducing mortality and morbidity.
Purpose of the Study:
- To evaluate the outcomes of myocardial infarction patients treated with a specific medical policy.
- To assess the impact of structured follow-up on patient recovery and complication detection.
Main Methods:
- Retrospective analysis of 773 consecutive myocardial infarction cases (706 individuals) from 1984-85.
- Inclusion of hospital mortality and 2-year follow-up data.
- Assessment of medical treatment policies, including beta-blocker, antiarrhythmic, and digitalis use.
- Routine exercise electrocardiogram (ECG) before discharge and at 6 weeks.
Main Results:
- Hospital mortality was 12.9% overall and 8.9% in patients under 70.
- Two-year mortality for ischemic heart disease was 14.4% overall and 9.5% in patients under 70.
- Overall 2-year mortality (all causes) was 20.3% and 14.6% for patients under 70.
- Frequent use of beta-adrenergic blocking agents and restricted use of antiarrhythmic drugs and digitalis were noted.
- Structured follow-up with exercise ECG improved early complication detection and treatment optimization.
Conclusions:
- A structured follow-up protocol, including exercise ECG, aids in early detection of complications and optimizes treatment for myocardial infarction patients.
- The study highlights the potential benefits of early intervention and specific medical management strategies in improving patient outcomes.
- Beta-adrenergic blocking agents were frequently utilized, even in cases of heart failure, suggesting a favorable risk-benefit profile in this cohort.